Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Short term Debt: 2016-2025

Historic Short term Debt for Rhythm Pharmaceuticals (RYTM) over the last 1 years, with Sep 2025 value amounting to $5.6 million.

  • Rhythm Pharmaceuticals' Short term Debt was N/A to $5.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.6 million, marking a year-over-year change of. This contributed to the annual value of $1.5 million for FY2024, which is N/A change from last year.
  • Latest data reveals that Rhythm Pharmaceuticals reported Short term Debt of $5.6 million as of Q3 2025, which was up 47.06% from $3.8 million recorded in Q2 2025.
  • Over the past 5 years, Rhythm Pharmaceuticals' Short term Debt peaked at $5.6 million during Q3 2025, and registered a low of $1.5 million during Q4 2024.
  • For the 2-year period, Rhythm Pharmaceuticals' Short term Debt averaged around $3.1 million, with its median value being $2.7 million (2025).